Youth-onset type 2 diabetes is increasing in prevalence and is associated with accelerated development of microvascular and macrovascular complications.1,2,3,4,5,6 Treatment of hypertension and nephropathy with angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) and treatment of hyperlipidemia with statins are known to prevent or slow progression of kidney disease and reduce cardiovascular events.7,8,9 To reduce early morbidity in young adults with diabetes, these medications need to be used. This evidence concerns the gene ACE and kidney disorder.